Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Year: 2018
Type: article
Abstract: ibrutinib plus venetoclax, are evaluating ibrutinib-based combinations to further improve outcomes in this rare, aggressive lymphoma, particularly for patients with high-risk disease requiring innovative therapies.
Source: Haematologica
Institutions: University of Plymouth, LMU Klinikum, Ludwig-Maximilians-Universität München, Hackensack University Medical Center, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Barts Cancer Institute, Washington University in St. Louis, Universidad Complutense de Madrid, Hospital Universitario Infanta Leonor, Janssen Research & Development (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2900472144